


AMENDMENTS TO THE CLAIMS


1. (Currently Amended) An oxygen infusion for increasing an oxygen concentration in tumor tissues in living bodies, said oxygen infusion comprising a dispersion of an albumin clathrate compound including porphyrin metal complex, dispersed in a physiologically permissible aqueous media, wherein said porphyrin metal complex is a porphyrin metal complex represented by the general formula (I):

General formula (I)



where R1 is a chain or alicyclic hydrocarbon group that may have one or more substituents, R2 is a basic axial ligand expressed by the formula (A):

Formula (A)



where R₃ is alkylene, R₄ is a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M, and M is a transition metal ion of the 4th or 5th period of the periodic table of elements.

2. (Canceled)

3. (Currently Amended) The oxygen infusion according to ~~claim 2~~ claim 1, wherein said porphyrin metal complex is a porphyrin metal complex of the general formula (I), in which R₁ is ~~C₁-C₁₉ chain hydrocarbon group having dimethyl groups at the first position or C₃-C₁₉ alicyclic hydrocarbon having a substituent at the first position~~, R₂ is a basic axial ligand expressed by the formula (A) where R₃ is C₁-C₁₀ alkylene, R₄ is hydrogen, methyl, ethyl or propyl, ~~R₅ is C₁-C₁₀ alkylene, R₆ is C₁-C₁₈ alkyl, and~~ M is Fe or Co.

4. (Canceled)

5. (New) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is a porphyrin metal complex of the general formula (I), in which R₁ is a C₁-C₁₉ chain hydrocarbon group having dimethyl groups at the first position, R₂ is a basic axial ligand

expressed by the formula (A) where R_3 is C_1 - C_{10} alkylene, R_4 is hydrogen, methyl, ethyl or propyl and M is Fe or Co.


6. (New) The oxygen infusion according to claim 1, wherein said one or more substituents are those selected from the group consisting of methyl, C_1 - C_{18} alkyl amide, C_1 - C_{18} alkanoyloxy, and C_1 - C_{18} alkoxy.

7. (New) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is 2-8-(2-methyl-1-imidazolyl)octanoyloxymethyl-5, 10, 15, 20-tetrakis-($\alpha,\alpha,\alpha,\alpha$ -o-pivaloylamidophenyl)porphyrin iron (II) complex.


8. (New) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is 2-8-(1-imidazolyl)octanoyloxymethyl-5, 10, 15, 20-tetrakis-($\alpha,\alpha,\alpha,\alpha$ -o-(1-methyl cyclohexanoyl) aminophenyl) porphyrin iron (II) complex.

9. (New) The oxygen infusion according to claim 1, wherein said albumin clathrate compound further includes a porphyrin metal complex represented by the general formula (II):

General formula (II)



where R_7 is hydrogen or a chain hydrocarbon group that may have one or more substituents, R_8 is alkyloxy, alkylamino, or an amino acid or amino acid derivative residue, R_9 is a basic axial ligand represented by the formula (C):



where R_{10} is alkylene, R_{11} is a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M, an M is a transition metal ion of the 4th or 5th period of the periodic table of elements.

10. (New) The oxygen infusion according to claim 9, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which R_7 is hydrogen, vinyl, ethyl or methoxy, R_8 is C_1 - C_{18} alkyloxy, C_1 - C_{18} alkylamino, an amino acid or a derivative residue of the amino acid, R_{10} is C_1 - C_{10} alkylene, R_{11} is hydrogen, methyl, ethyl or propyl, and M is Fe or Co.


11. (New) The oxygen infusion according to claim 9, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which said one or

more substituents are selected from the group consisting of methyl, C₁-C₁₈ alkylamide, C₁-C₁₈ alkanoyloxy and C₁-C₁₈ alkoxy.

12. (New) The oxygen infusion according to claim 9, wherein said porphyrin metal complex of the general formula (II) is 8,13-bisvinyl-2-methoxycarbonylethyl-18-(3-(1-imidazolyl) propylamino) carbonylethyl-3,7,12,17-tetramethyl porphyrin iron (II) complex.


13. (New) The oxygen infusion according to claim 1, where said albumin clathrate compound further includes a porphyrin metal complex represented by the general formula (II):

General formula (II)



wherein R_7 is hydrogen or a chain hydrocarbon group that may have one or more substituents, R_8 is alkyloxy, alkylamino, or an amino acid or amino acid derivative residue, R_9 is a basic axial ligand expressed by the formula (D):

Formula (D)



where R₁₂ is alkyl, and M is a transition metal ion of the 4th or 5th period of the periodic table of elements.

14. (New) The oxygen infusion according to claim 13, wherein R₇ is hydrogen, vinyl, ethyl or methoxy, R₈ is C₁-C₁₈ alkyloxy, C₁-C₁₈ alkylamino, amino acid or a derivative residue thereof, R₁₂ is C₁-C₁₈ alkyl, and M is Fe or Co.

15. (New) The oxygen infusion according to claim 13, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which said one or more substituents are the ones selected from the group consisting of methyl, C₁-C₁₈ alkylamide, C₁-C₁₈ alkanoyloxy and C₁-C₁₈ alkoxy.